Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Should You Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $6.81, but opened at $7.41. Gyre Therapeutics shares last traded at $7.73, with a volume of 54,810 shares changing hands.

Wall Street Analysts Forecast Growth

GYRE has been the topic of several analyst reports. Wall Street Zen raised Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Jefferies Financial Group assumed coverage on shares of Gyre Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Gyre Therapeutics has an average rating of “Hold” and an average target price of $17.00.

Gyre Therapeutics Stock Performance

The stock has a market cap of $755.23 million, a price-to-earnings ratio of 261.42 and a beta of 1.99. The company’s 50 day simple moving average is $7.60 and its 200 day simple moving average is $7.65.

Hedge Funds Weigh In On Gyre Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GYRE. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after buying an additional 1,402 shares during the period. Alliancebernstein L.P. raised its position in Gyre Therapeutics by 9.5% in the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after acquiring an additional 1,900 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after acquiring an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of Gyre Therapeutics during the 3rd quarter valued at about $38,000. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.